Journal of Ophthalmology / 2017 / Article / Tab 1

Clinical Study

Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study

Table 1

Univariate analysis of baseline demographics and recurrence in the eyes with retinopathy of prematurity in Zone II Stage 3 after ranibizumab treatment.

Recurrence (18 eyes)Favorable outcome (62 eyes) value

Baseline characteristics
 Patients1131 
 Birth weight (g)1204.09 ± 321.361356.61 ± 505.100.311a
 Gestation age (weeks)28.82 ± 1.3629.72 ± 2.390.112a
 Male5171.000b
 Multiple gestation2110.713b
 Respiratory distress syndrome4110.481b
 Sepsis011.000b
 HIE100.262b
 Anemia4120.720b
 Pneumonia161.000b
 Hypotension110.387b
 Carbohemia110.387b
 Intraventricular hemorrhage281.000b
 Blood transfusion281.000b
 Oxygen administration6201.000b
 Surfactant070.654b
 Vitamin E121.000b
 Hormones100.262b
Factors during pregnancy
 Preeclampsia220.558b
 Placental abruption040.330b
 Intrauterine hypoxia130.558b
ROP findings
Preretinal hemorrhage before treatment560.000b
Preretinal hemorrhage after treatment020.216b
Iris neovascularization100.349b
Threshold17520.254b

aIndependent samples t-test.
bChi-square test.
SD: standard deviation; HIE: hypoxic ischemic encephalopathy; ROP: retinopathy of prematurity.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.